EU/3/05/344: Orphan designation for the treatment of medullary thyroid carcinoma

Vandetanib

Table of contents

Overview

Please note that this product was withdrawn from the Community Register of designated orphan medicinal products in August 2010 on request of the sponsor.

On 24 January 2006, orphan designation (EU/3/05/344) was granted by the European Commission to AstraZeneca UK Limited, United Kingdom, for vandetanib for the treatment of medullary thyroid carcinoma.

Key facts

Active substance
Vandetanib
Intended use
Treatment of medullary thyroid carcinoma
Orphan designation status
Withdrawn
EU designation number
EU/3/05/344
Date of designation
24/01/2006
Sponsor
AstraZeneca UK Limited
Medical Information
Horizon Place
600 Capability Green
Luton LU1 3LU
United Kingdom
E-mail: medical.informationuk@astrazeneca.com

Documents related to this orphan designation evaluation

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

EU register of orphan medicines

The list of medicines that have received an orphan designation in the EU is available on the European Commission's website:

How useful was this page?

Add your rating